Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Singulair Allergy Switch Must Address Neuropsychiatric Concerns

This article was originally published in The Tan Sheet

Executive Summary

FDA will ask the Nonprescription Drug Advisory Committee May 2 to weigh the risks and benefits of switching Merck’s Singulair Allergy 10 mg montelukast sodium for allergy relief. Among the agency’s concerns about potential neuropsychiatric events and off-label use by children and asthmatics.

Advertisement

Related Content

Merck Singulair Switch NDA Limits Indication to Allergies, Omits Asthma

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS106886

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel